JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

JNJ

167.69

-0.36%↓

NVS

116.94

-0.3%↓

ABT

128.18

+0.74%↑

MDT

92.11

-0.35%↓

ELV.US

287.61

-2.37%↓

Search

Novo Nordisk A-S

Abierto

SectorSanidad

50.63 -6.19

Resumen

Variación precio

24h

Actual

Mínimo

50.03

Máximo

54.86

Métricas clave

By Trading Economics

Ingresos

804M

29B

Ventas

-7.6B

78B

P/B

Media del Sector

18.649

40.048

BPA

6.53

Rentabilidad por dividendo

2.34

Margen de beneficios

37.182

Empleados

77,406

EBITDA

5.9B

46B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+45.22% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.34%

2.45%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

50B

316B

Apertura anterior

56.82

Cierre anterior

50.63

Noticias sobre sentimiento de mercado

By Acuity

68%

32%

349 / 375 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Novo Nordisk A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 12:41 UTC

Ganancias

Novo Nordisk Shares Plummet on Guidance Cut as Wegovy Knockoffs Hurt Sales -- 2nd Update

29 jul 2025, 11:36 UTC

Ganancias

Novo Nordisk Cuts Guidance as Copycat Versions of Wegovy Hurt Results

29 jul 2025, 17:05 UTC

Ganancias

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29 jul 2025, 16:55 UTC

Ganancias

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29 jul 2025, 13:35 UTC

Ganancias

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29 jul 2025, 11:39 UTC

Ganancias

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

29 jul 2025, 11:11 UTC

Ganancias

Novo Nordisk Shares Fall Over 15% After Guidance Cut

29 jul 2025, 11:09 UTC

Ganancias

Novo Nordisk: Sales Outlook Reflects Persistent Use of Compounded GLP-1s, Slower Mkt Expansion, Competition

29 jul 2025, 11:08 UTC

Ganancias

Novo Nordisk: Lowered Sales Outlook Driven by Lower Growth Views for Wegovy, Ozempic in U.S.

29 jul 2025, 11:08 UTC

Ganancias

Novo Nordisk Had Seen 2025 Sales Growth at 13%-21%, Op Profit Growth at 16%-24%

29 jul 2025, 11:07 UTC

Ganancias

Novo Nordisk Cuts 2025 Sales and Op Profit Guidance

29 jul 2025, 11:06 UTC

Ganancias

Novo Nordisk 1H Sales Increased by 18% and Operating Profit Increased by 29%

29 jul 2025, 11:06 UTC

Ganancias

Novo Nordisk Now Sees 2025 Sales Growth at 8%-14%, Op Profit Growth at 10%-16%

29 jul 2025, 11:05 UTC

Ganancias

Novo Nordisk Cuts Sales and Operating Profit Outlook for 2025

15 jul 2025, 12:38 UTC

Charlas de Mercado

Novo Nordisk Faces Several Questions on Wegovy -- Market Talk

9 jul 2025, 10:59 UTC

Charlas de Mercado

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 jul 2025, 09:17 UTC

Acciones populares

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

24 jun 2025, 10:26 UTC

Charlas de Mercado

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

23 jun 2025, 13:09 UTC

Charlas de Mercado

Novo Nordisk Drug Data Doesn't Change Anything -- Market Talk

20 jun 2025, 13:31 UTC

Adquisiciones, fusiones, absorciones

E.l.f. Beauty CEO Buys Up Smucker Stock -- Barrons.com

13 jun 2025, 11:39 UTC

Charlas de Mercado

Novo Nordisk Skips to Late-Stage Development of New Obesity Drug -- Market Talk

13 jun 2025, 10:04 UTC

Charlas de Mercado

Novo Nordisk Overtakes SAP to Reclaim Spot as Europe's Most Valuable Company -- Market Talk

11 jun 2025, 09:45 UTC

Charlas de Mercado

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

10 jun 2025, 13:38 UTC

Acciones populares

Stocks to Watch Tuesday: Tesla, TSMC, Novo Nordisk -- WSJ

9 jun 2025, 10:09 UTC

Charlas de Mercado

Novo Nordisk Valuation Presents a Good Opportunity -- Market Talk

3 jun 2025, 15:03 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

29 may 2025, 01:00 UTC

Principales Noticias

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

20 may 2025, 14:08 UTC

Ganancias

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

20 may 2025, 07:43 UTC

Charlas de Mercado

Novo Nordisk Guidance at Risk After CEO News -- Market Talk

16 may 2025, 18:35 UTC

Principales Noticias

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S previsión

Precio Objetivo

By TipRanks

45.22% repunte

Estimación a 12 Meses

Media 78.33 USD  45.22%

Máximo 90 USD

Mínimo 55 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

62.63 / 69.23Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

349 / 375 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.